News Related to Second-Generation Atypical Antipsychotic

Related coverage linked through entity extraction aliases.

Teva Reports Positive Long-Term IBD Data for Duvakitug, FDA Accepts TEV-749 Application

Mar 01, 2026

Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.

FDA Accepts Teva's Application for Once-Monthly Olanzapine Injection for Schizophrenia

Feb 21, 2026

The FDA has accepted Teva Pharmaceuticals' New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine injection for treating schizophrenia in adults, based on Phase 3 trial data showing efficacy consistent with existing formulations without requiring post-injection monitoring.